Curis (NASDAQ:CRIS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Curis (NASDAQ:CRIS) in a report issued on Tuesday,Benzinga reports. The firm currently has a $20.00 price target on the biotechnology company’s stock.

Curis Price Performance

Curis stock opened at $3.72 on Tuesday. The stock has a market capitalization of $31.50 million, a PE ratio of -0.48 and a beta of 3.35. The business has a 50 day simple moving average of $4.50 and a 200-day simple moving average of $5.79. Curis has a 12 month low of $3.51 and a 12 month high of $17.49.

Hedge Funds Weigh In On Curis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRIS. Focused Wealth Management Inc increased its stake in shares of Curis by 63.1% during the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after buying an additional 96,256 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after acquiring an additional 10,097 shares during the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.